Swine Influenza is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Swine Influenza have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Swine Influenza compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Swine Influenza overview
Swine influenza is an infection caused by any of several types of swine influenza viruses. Swine influenza virus (SIV) or swine-origin influenza virus (S-OIV) refers to any strain of the influenza family of viruses that is endemic in pigs. In humans the symptoms “swine flu” H1N1 virus are similar to influenza and influenza-like illness. Symptoms include fever, cough, sore throat, watery eyes, body aches, shortness of breath, headache, weight loss, chills, sneezing, runny nose, coughing, dizziness, abdominal pain, lack of appetite, and fatigue. The CDC recommends real-time PCR as the method of choice for diagnosing H1N1. Vaccines are available for different kinds of swine flu.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Swine Influenza, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.